922732-20-5

Basic information

• Product Name: cyclopropanesulfonic acid [(Z)-(1S,4R,6S,18R)18-ethoxymethoxy-14-(4-methoxybenzyl)-2,15-dioxo-3,14,16-triaza-tricyclo[14.3.0.0*4,6*]nonadec-7-ene-4-carbonyl]amide
• Synonyms: cyclopropanesulfonic acid [(Z)-(1S,4R,6S,18R)18-ethoxymethoxy-14-(4-methoxybenzyl)-2,15-dioxo-3,14,16-triaza-tricyclo[14.3.0.0*4,6*]nonadec-7-ene-4-carbonyl]amide
• CAS NO: 922732-20-5
• Molecular Weight: 632.778
• Mol File: 922732-20-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: cyclopropanesulfonic acid [(Z)-(1S,4R,6S,18R)18-ethoxymethoxy-14-(4-methoxybenzyl)-2,15-dioxo-3,14,16-triaza-tricyclo[14.3.0.0*4,6*]nonadec-7-ene-4-carbonyl]amide(CAS DataBase Reference)
• NIST Chemistry Reference: cyclopropanesulfonic acid [(Z)-(1S,4R,6S,18R)18-ethoxymethoxy-14-(4-methoxybenzyl)-2,15-dioxo-3,14,16-triaza-tricyclo[14.3.0.0*4,6*]nonadec-7-ene-4-carbonyl]amide(922732-20-5)
• EPA Substance Registry System: cyclopropanesulfonic acid [(Z)-(1S,4R,6S,18R)18-ethoxymethoxy-14-(4-methoxybenzyl)-2,15-dioxo-3,14,16-triaza-tricyclo[14.3.0.0*4,6*]nonadec-7-ene-4-carbonyl]amide(922732-20-5)

Safety Data

• Hazardous Substances Data: 922732-20-5(Hazardous Substances Data)

Upstream product

• 154350-29-5 cyclopropanesulphonamide 
• 922732-19-2 C₂₈H₃₇N₃O₆ 

Relevant articles and documents

HCV INHIBITING MACROCYCLIC PHENYLCARBAMATES

Compounds of the Formula (I) including a stereoisomer thereof, or an N-oxide, a pharmaceutically acceptable addition salt, or a pharmaceutically acceptable addition solvate thereof;usefulas HCV inhibitors; processes for preparing these compounds as well a

MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS

Inhibitors of HCV replication of formula (I) and the N-oxides, salts, or stereoisomers thereof, wherein each dashed line represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is -OR6, -NH-SO2R7; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, or C3-7cycloalkyl; n is 3, 4, 5, or 6; R4 and R5 taken together with the nitrogen atom to which they are attached form a bicyclic ring system selected from formula (II) wherein said ring system may optionally be substituted with 1-3 substituents; R6 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R7 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl or naphthyl, each of which may be optionally substituted with 1-3 substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms each independently selected from N, O or S, and being optionally substituted with 1-3 substituents pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.